Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nature communications·2026

Same author

Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Cancer immunology research·2026

Same author

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Nature cancer·2026

Same author

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma.

Blood cancer discovery·2025

Same author

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025

Same author

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025

Same journal

Characterization and quantitation of baculoviral DNA in rAAV vectors produced in Sf9 cells.

Molecular therapy. Methods & clinical development·2026

Same journal

<i>In vivo</i> delivery of a fluorogenic antisense oligonucleotide into human leukocytes in a humanized mouse model system.

Molecular therapy. Methods & clinical development·2026

Same journal

Development of high-throughput analytical methods for characterization and quantitation of rAAV genome integrity.

Molecular therapy. Methods & clinical development·2026

Same journal

Morphological changes induced by buffer exchange during preparation of mRNA-lipid nanoparticles occur in a stepwise manner as pH is elevated.

Molecular therapy. Methods & clinical development·2026

Same journal

Targeted inhibition of <i>ELANE</i> expression using adenine base editing to treat severe congenital neutropenia.

Molecular therapy. Methods & clinical development·2025

Same journal

AAV-PHP.eB achieves superior neuronal transduction over AAV9 in pigtail macaques following intracerebroventricular administration.

Molecular therapy. Methods & clinical development·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 2, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Dendritic Cell Therapies for Hematologic Malignancies.

Matthew Weinstock¹, Jacalyn Rosenblatt¹, David Avigan¹

¹Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Molecular Therapy. Methods & Clinical Development

|May 9, 2017

Summary

This summary is machine-generated.

Dendritic cells (DCs) are key immune cells used in new cancer vaccines. This review explores how DC-based vaccines are improving immunotherapy for blood cancers.

Keywords:

AML cancer immunotherapy dendritic cell multiple myeloma tumor immunology vaccine

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice

Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice

Published on: July 1, 2022

Related Experiment Videos

Last Updated: Mar 2, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice

Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice

Published on: July 1, 2022

Area of Science:

Immunology
Oncology
Vaccinology

Background:

Dendritic cells (DCs) are crucial antigen-presenting cells in cancer immunity.
DCs play vital roles in recognizing, eliminating, and tolerating cancer.
Their immunologic functions are being leveraged for novel cancer therapies.

Purpose of the Study:

To review the advancement of dendritic cell (DC)-based anti-tumor vaccines.
To summarize current treatment strategies utilizing DC-based vaccines for hematologic malignancies.
To highlight the progress of DC-based vaccines in clinical trials.

Main Methods:

Review of current scientific literature on DC-based vaccines.
Analysis of clinical trial data for DC-based immunotherapies.
Synthesis of information on DC vaccine strategies in hematologic cancers.

Main Results:

Several DC-based anti-tumor vaccines are in clinical trials for blood cancers.
DC-based vaccines represent a promising area of cancer immunotherapy.
These vaccines harness the unique capabilities of DCs for therapeutic benefit.

Conclusions:

Dendritic cell-based vaccines are advancing immunotherapy for hematologic malignancies.
Ongoing clinical trials are evaluating the efficacy of these novel vaccines.
DC-based vaccines offer a promising avenue for future cancer treatment strategies.